We are live on
!
Find out more
SGH
Sivik Global Healthcare Portfolio holdings
AUM
$132M
1-Year Est. Return
24.1%
This Fund
S&P 500
This Quarter
Est. Return
-5.27%
1 Year Est. Return
+24.1%
3 Year Est. Return
+53.78%
5 Year Est. Return
+97.1%
10 Year Est. Return
+690.63%
AUM
$132M
AUM Growth
-$213M
(-62%)
Cap. Flow
-$204M
Cap. Flow
% of AUM
-154.6%
Top 10 Holdings %
Top 10 Hldgs %
46.58%
Holding
55
New
6
Increased
2
Reduced
24
Closed
21
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Waters Corp
WAT
|
+$5.13M |
| 2 |
Johnson & Johnson
JNJ
|
+$4.66M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$3.06M |
| 4 |
Elevance Health
ELV
|
+$1.64M |
| 5 |
CVS Health
CVS
|
+$1.54M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P Biotech ETF
XBI
|
+$9.36M |
| 2 |
HCA Healthcare
HCA
|
+$7M |
| 3 |
McKesson
MCK
|
+$4.46M |
| 4 |
Medtronic
MDT
|
+$4.32M |
| 5 |
Repligen
RGEN
|
+$4.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 81.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
UnitedHealth
UNH
$364B
| $2.71M | 2.05% |
10,000
-2,000
| -17% | -$596K |
|
27
Globus Medical
GMED
$11.5B
| $2.58M | 1.96% |
30,000
-10,000
| -25% | -$898K |
|
28
Abbott
ABT
$192B
| $2.57M | 1.95% |
25,000
-15,000
| -38% | -$1.69M |
|
29
Edwards Lifesciences
EW
$53.6B
| $1.6M | 1.22% |
20,000
-15,000
| -43% | -$1.24M |
|
30
Smith & Nephew
SNN
$12.5B
| $1.59M | 1.21% |
50,000
-75,000
| -60% | -$2.55M |
|
|
31
Elevance Health
ELV
$86.6B
| $1.46M | 1.11% |
+5,000
| New | +$1.64M |
|
32
Encompass Health
EHC
$12.3B
| $1.45M | 1.1% |
15,000
-35,000
| -70% | -$3.59M |
|
|
33
CVS Health
CVS
$121B
| $1.44M | 1.09% |
+20,000
| New | +$1.54M |
|
34
Alnylam Pharmaceuticals
ALNY
$30B
| – | – |
-3,000
| Closed | -$1.19M |
|
35
argenx
ARGX
$54.8B
| – | – |
-1,500
| Closed | -$1.26M |
|
36
Becton Dickinson
BDX
$50B
| – | – |
-20,000
| Closed | -$3.88M |
|
37
Bruker
BRKR
$9.03B
| – | – |
-65,000
| Closed | -$3.06M |
|
38
CG Oncology
CGON
$6.82B
| – | – |
-35,000
| Closed | -$1.45M |
|
39
GE HealthCare
GEHC
$32.6B
| – | – |
-35,000
| Closed | -$2.87M |
|
|
40
HCA Healthcare
HCA
$89.8B
| – | – |
-15,000
| Closed | -$7M |
|
|
41
Medtronic
MDT
$116B
| – | – |
-45,000
| Closed | -$4.32M |
|
|
NVO
42
Novo Nordisk
NVO
$203B
| – | – |
-75,000
| Closed | -$3.82M |
|
|
43
Repligen
RGEN
$9.35B
| – | – |
-25,000
| Closed | -$4.1M |
|
|
SEM
44
DELISTED
Select Medical
SEM
| – | – |
-190,000
| Closed | -$2.82M |
|
45
Surgery Partners
SGRY
$2.01B
| – | – |
-200,000
| Closed | -$3.09M |
|
46
Bio-Techne
TECH
$11.3B
| – | – |
-45,000
| Closed | -$2.65M |
|
Similar funds
AFP
PCGDR
ACM
9C
STFP
ADEF
AC
CIP
Sivik Global Healthcare's Q1 2026 Portfolio in Review
As of Q1 2026, Sivik Global Healthcare held 55 positions worth $132M, down 62% from $345M the previous quarter. Its ten largest holdings account for 47% of the portfolio.
Sivik Global Healthcare withdrew a net $204M in Q1 2026, closing 21 positions and reducing 24 holdings. Its most notable exit was HCA Healthcare, an estimated $7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 51% a quarter earlier.
Against the trend, Sivik Global Healthcare opened a new position in Waters Corp worth $4.47M.
- Sivik Global Healthcare's largest Q1 2026 buy was Waters Corp: 15,000 shares worth $4.47M.
- Sivik Global Healthcare added most to Merck in Q1 2026, an estimated $1.15M increase.
- Sivik Global Healthcare's biggest Q1 2026 reduction was State Street SPDR S&P Biotech ETF, cutting an estimated $9.36M.
- Sivik Global Healthcare fully exited HCA Healthcare in Q1 2026, selling an estimated $7M.
- Sivik Global Healthcare's ten largest holdings make up 47% of its $132M portfolio in Q1 2026.
- Sivik Global Healthcare opened 6 new positions and closed 21 in Q1 2026.
- Sivik Global Healthcare's portfolio value fell 62% quarter-over-quarter to $132M.
Based on Sivik Global Healthcare's 13F filing for Q1 2026, filed 15 Apr 2026.